Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > In Vitro Testing

In Vitro Testing

In Vitro Testing refers to the evaluation of biological, chemical, or physical properties of a substance, product, or process outside of a living organism.
This technique is commonly used in scientific research, pharmaceutical development, and toxicology studies to assess the safety, efficacy, and mechanisms of various compounds or procedures prior to in vivo (animal or human) testing.
In Vitro Testing allows for controlled, reproducible experiments that can provide valuable insights into cellular, molecular, and biochemical processes without the complexities of a living system.
This approach enables researchers to optimize protocols, identfy lead candidates, and streamline the development of new therapies or products in a more cost-efective and efficient manner.

Most cited protocols related to «In Vitro Testing»

1
Comprehensive Autophagy Modulator Database
To provide comprehensive information of autophagy modulators for researchers, we searched not only for related proteins, but also related chemicals and microRNAs from peer-reviewed literatures, available databases and some websites. The detailed collection processes are described as follows.
Related proteins: Firstly, we searched and reviewed autophagy-related scientific articles recorded by PubMed as many as possible and extracted some useful information for us. In this step, we collected 545 autophagy-related genes from 499 literatures after removing duplicates. For these genes, their molecular type, specific effects on autophagy (e.g., their increased/decreased activity will increase/decrease autophagy), species evidence and corresponding experimental references were reserved. Additionally, their pathway and disease information have also been added including canonical pathways, downstream microRNAs, proteins and chemicals, upstream proteins and chemicals, role in cell, involved disease, OMIM information, KEGG disease information. After that, we searched for the autophagy-related database and found two excellent databases: Human Autophagy Database (HADb, http://www.autophagy.lu/) and the autophagy database (http://www.tanpaku.org/autophagy/, human). From them, we obtained 251 new related genes and their pathway information were collected from Autophagy Regulatory Network database. For all the collected genes, their corresponding uniport ID (Homo sapiens) and protein description were compiled manually. And then, 20 external database links containing structural and biological information were added: Gene ID, GI number, Uni Gene, PDB, disport, BioGrid, MINT, String, ChEMBL, DrugBank, Guide to Phar, Swisslipids, Biomuta, Ensembl protein, KEGG, Pharm GKB, Biocyc, Reactome, Unipathway, and Gene wiki.
Related chemicals: Similar to the protein collection process, we firstly collected 246 related chemicals from 367 literatures recorded by PubMed. For these chemicals, their molecular type, specific effects on autophagy (e.g., their increased/decreased activity will increase/decrease autophagy), species evidence and corresponding experimental references were reserved. Additionally, some pathway and disease information including target, pathway, biological description and corresponding gene name listed in aforementioned protein database. After that, we also obtained 595 new chemicals from MedChem Express, Selleck and APExBIO. Their research area, category (activator/inhibitor), in vitro/vivo test, clinical trials were reserved. For all the chemicals, some basic information was collected: IUPAC name, alternative names, canonical SMILES, molecular formula, molecular weight, solubility. Furthermore, 18 important physicochemical and ADME properties were calculated by our ADMETlab platform and chemopy package [22 (link)]: hydrogen acceptor, hydrogen donor, logD (pH = 7), pKa (pH = 7), pKb (pH = 7), druglike, logP(o/w), logS, SlogP, TPSA, loghERG, Caco-2, logBB, MDCK, logKp, logKhsa, human oral absorption, and percent human oral absorption (%). Four external links including structural and drug information were added: CAS number, PubChem CID, HMDB ID, and DrugBank ID.
Related microRNAs: In this part, we totally collected 132 autophagy related microRNAs from literatures recorded by PubMed and a noncoding RNA database, ncRDeathDB (www.rna-society.org/ncrdeathdb) after removing some duplicates [23 (link)]. Their molecular type, specific effects on autophagy (e.g., their increased/decreased activity will increase/decrease autophagy), species evidence and corresponding experimental references were reserved. Additionally, the gene description, RefSeq status, organism, synonyms and miRbase ID were also compiled to supply the biological information.
Wang N.N., Dong J., Zhang L., Ouyang D., Cheng Y., Chen A.F., Lu A.P, & Cao D.S. (2018). HAMdb: a database of human autophagy modulators with specific pathway and disease information. Journal of Cheminformatics, 10, 34.
Publication 2018
Autophagy Biopharmaceuticals Cells Genes Homo sapiens Hydrogen In Vitro Testing Mentha MicroRNAs Pharmaceutical Preparations Post-Translational Protein Processing Proteins RNA, Untranslated Tissue Donors Uniport
2
Isolation and Characterization of Ginger-Derived Nanoparticles

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Bicarbonate, Sodium Bile Biological Assay Copper Electricity Farmers Formvar Intestines In Vitro Testing isolation Lilianae Microscopy, Atomic Force Pancreatin Pepsin A Phosphates Proteins RRAD protein, human Saline Solution Stomach Sucrose Transmission Electron Microscopy Ultrasonics uranyl acetate Zingiberaceae Zingiberales Zingiber officinale
3
In vitro Antiplasmodial Activity Assay
The in vitro antiplasmodial activity of test compounds was determined using the malaria SYBR Green I-based fluorescence assay described by Smilkstein et al. [26] (link), with minor modifications. Briefly, P. falciparum-infected erythrocytes were incubated in culture medium containing two-fold dilutions of the test compounds in 96-well microtiter plates. Assays were initiated with ring-stage P. falciparum-infected erythrocytes at a hematocrit and parasitemia of 1%. Wells containing infected erythrocytes in the presence of chloroquine (0.25–2 µM) served as zero growth controls and wells containing infected erythrocytes in the absence of chloroquine or test compounds served as 100% parasite growth controls. Plates were incubated at 37°C under an atmosphere of 96% nitrogen, 3% carbon dioxide and 1% oxygen for 96 h, before 100 µL from each well was mixed with 100 µL of SYBR Safe DNA gel stain (0.2 µL/mL) in 20 mM Tris, pH 7.5, 5 mM ethylenediaminetetraacetic acid (EDTA), 0.008% (w/v) saponin, 0.08% (v/v) Triton X-100, in a second 96-well microtitre plate. Fluorescence was measured using a FLUOstar OPTIMA multidetection microplate reader from BMG LABTECH with excitation and emission wavelengths of 490 and 520 nm, respectively. The 50% inhibitory concentration (IC50) of each test compound under each test condition was calculated by fitting the data to a sigmoidal curve (typically y = a/(1+ (x/x0)b) using nonlinear least squares regression (SigmaPlot, Systat Software) and averaging the IC50 estimates from independent experiments.
Spry C., Macuamule C., Lin Z., Virga K.G., Lee R.E., Strauss E, & Saliba K.J. (2013). Pantothenamides Are Potent, On-Target Inhibitors of Plasmodium falciparum Growth When Serum Pantetheinase Is Inactivated. PLoS ONE, 8(2), e54974.
Publication 2013
Atmosphere Biological Assay Carbon dioxide Chloroquine Culture Media Edetic Acid Erythrocytes Fluorescence In Vitro Testing Malaria Nitrogen Oxygen Parasite Control Parasitemia Psychological Inhibition Saponin Stains SYBR Green I Technique, Dilution Triton X-100 Tromethamine Volumes, Packed Erythrocyte
4
Cytotoxicity Evaluation of Nanomaterials
Rat NR8383 cells [60 (link), 61 (link)] were originally purchased from ATCC (USA) and cultured in F-12K medium supplemented with 2 mM glutamine, penicillin/streptomycin (100 U/10 mg/mL; and 15 % (v/v) fetal calf serum (FCS; all from PAN Biotech GmbH, Germany). Cells were grown in 500 mL flasks (Greiner, Germany) under standard cell culture conditions (37 °C; 5 % CO2) and passaged once a week. For the in vitro tests, cells were detached from the substrate by mechanical agitation, dispersed by pipetting, seeded into 96-well plates at 3 × 105 live cells per well and incubated in F-12K medium supplemented with 5 % FCS for 24 h. For test material application, supernatants were withdrawn, and test material-containing phenol red-free F-12K medium (Biochrom GmbH, Germany), supplemented with 2 mM glutamine and 100 U/100 μg/mL penicillin/streptomycin, was applied onto the cells. To correct for test material-specific adsorption and/or scattering of light, cell-free NM-containing controls were included in all test runs for all dilution steps. Cells were incubated with particles for 16 or 1.5 h. For the determination of LDH, GLU, and TNF-α release, cell culture supernatants were sampled after 16 h of incubation. In a parallel approach, supernatants were sampled after 1.5 h of incubation to assess H2O2 formation.
Wiemann M., Vennemann A., Sauer U.G., Wiench K., Ma-Hock L, & Landsiedel R. (2016). An in vitro alveolar macrophage assay for predicting the short-term inhalation toxicity of nanomaterials. Journal of Nanobiotechnology, 14, 16.
Publication 2016
Adsorption Cell Culture Techniques Cells Glutamine In Vitro Testing Light Penicillins Peroxide, Hydrogen Streptomycin Technique, Dilution Tumor Necrosis Factor-alpha
5
SARS-CoV-2 Serological Assay Optimization
Specimens for polymerase chain reaction (PCR) diagnostics were collected as oropharyngeal and nasopharyngeal swabs in eSwab (Copan) or Sigma-Virocult (MWE), respectively. Experimental details of RT-PCR reactions are in the eMethods in the Supplement.
The applied CE–in vitro diagnostic certified serological tests for SARS-CoV-2 have a high specificity according to the manufacturer’s documentation (Euroimmun SARS-CoV-2 IgG enzyme-linked immunosorbent assay [ELISA]: 99.6%, validated on 1344 samples; Roche Elecsys Anti-SARS-CoV-2 test: 99.81%, validated on 10 533 samples; Mikrogen recomWell ELISA: 98.7%, validated on 300 samples). With specificities less than 100%, however, false-positive results constitute a substantial proportion of all positive results in populations with a low seroprevalence. To increase specificity, both an ELISA test against the viral S1 protein as well as an immunofluorescence test on SARS-CoV-2–infected VeroE6 cells were performed for all samples. Discordant results were clarified by electrochemiluminescence immunoassays, a second ELISA, or an in-house Luminex-based assay.17 (link) We had previously determined that a combination of these complementary assays considerably increases the specificity of the results without compromising the sensitivity.16 The workflow of the serological analyses is shown eTable 1 in the Supplement; details of the serological analyses, the immunofluorescence assay, and the neutralization assay are given in the eMethods in the Supplement.
Tönshoff B., Müller B., Elling R., Renk H., Meissner P., Hengel H., Garbade S.F., Kieser M., Jeltsch K., Grulich-Henn J., Euler J., Stich M., Chobanyan-Jürgens K., Zernickel M., Janda A., Wölfle L., Stamminger T., Iftner T., Ganzenmueller T., Schmitt C., Görne T., Laketa V., Olberg S., Plaszczyca A., Cortese M., Bartenschlager R., Pape C., Remme R., Huzly D., Panning M., Weigang S., Giese S., Ciminski K., Ankerhold J., Kochs G., Schwemmle M., Handgretinger R., Niemeyer C.M., Engel C., Kern W.V., Hoffmann G.F., Franz A.R., Henneke P., Debatin K.M, & Kräusslich H.G. (2021). Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. JAMA Pediatrics, 175(6), 1-8.
Publication 2021
Biological Assay Cells Diagnosis Dietary Supplements Enzyme-Linked Immunosorbent Assay Hypersensitivity Immunoassay Immunofluorescence Immunosorbents In Vitro Testing Nasopharynx Oropharynxs Polymerase Chain Reaction Population Group SARS-CoV-2 Serodiagnosis Severe Acute Respiratory Syndrome Severe acute respiratory syndrome-related coronavirus Test, Clinical Enzyme Tests, Serologic Viral Proteins

Most recents protocols related to «In Vitro Testing»

1
Evaluation of MPV.10.34.d IRC Effectiveness
Not available on PMC !

Example 11

MPV.10.34.d IRC Effectiveness in Human Assays

While the in vitro functional test results of the above experiments were promising, the next desired step in the analysis was to perform similar experiments in human-based assays. To this end, the response of mock human cellular immune system components to tumor cells exposed to MPV.10.34.d IRC was examined in vitro. Human CMV (HCMV) was selected for this study since human CMV is highly prevalent (infecting 50-90% of the human population) and mostly asymptomatic in healthy individuals. (See, Longmate et al., Immunogenetics, 52(3-4):165-73, 2001; Pardieck et al., F1000Res, 7, 2018; and van den Berg et al., Med. Microbiol. Immunol., 208(3-4):365-373, 2019). Importantly, HCMV establishes a life-long persistent infection that requires long-lived cellular immunity to prevent disease. Hence, it is rational to hypothesize that a complex adaptive cell-mediated anti-viral immunity developed over many years to strongly control a viral infection in an aging person can be repurposed and harnessed to treat cancer.

In these experiments, CD8+ T cell responses to CMV peptides were tested in three different human tumor cell lines, including HCT116, OVCAR3, and MCF7. All three of these human tumor cell lines are HLA-A*0201 positive.

In vitro cytotoxicity assays. HTC112, human colon cancer cells, MCF7, human breast cancer cells, and OVCAR3, human ovarian cancer cells (all from ATCC, Manassas, VA, US) were seeded overnight at 0.01 to 0.2×106 per well per 100 μL per 96 well plate. The next day (about 20 to 22 hrs later), each cell line was incubated for one hour at 37° C. under the following conditions: (1) CMV peptide at a final concentration of 1 μg/mL (positive control), (2) MPV.10.34.d at a final concentration of 2.5 μg/mL (negative control), (3) CMV-conjugated MPV.10.34.d IRC at a final concentration of 2.5 μg/mL, (4) CMV-conjugated HPV16 IRC at a final concentration of 2.5 μg/mL, and (5) no antigen (negative control). After 1 hour, the cells were washed vigorously with 200 μL of media for three times to remove non-specific binding. Human patient donor CMV T cells (ASTARTE Biologics, Seattle, WA, US) were added at the E:T (effector cell:target cell) ratio of 10:1 and incubated in a tissue culture incubator for 24 hrs at 37 C, 5% CO2. The total final volume of each sample after co-culture was 200 μL. Cell viability was measured after co-culturing. Cell viability was measured with CELLTITER-GLO® (Promega, Madison, WI, US). This assay provides a luciferase-expressing chemical probe that detects and binds to ATP, a marker of cell viability. The amount of ATP generated from tumor cells was quantified according to manufacturer protocols. In these assays, reduced luciferase activity indicates cell death and suggests greater immune redirection and greater cytotoxicity.

The results are provided in FIG. 25. CMV-conjugated MPV.10.34.d IRC (“VERI-101” in FIGS. 25A, 25B, and 25C) was equally effective as CMV-conjugated HPV16 IRC (“CMV AIR-VLP” in FIGS. 25A, 25B, and 25C) in redirecting human healthy donor CMV pp65-specific CD8+ T-cells (Astarte Biologics, Inc., Bothell, WA, US) to kill immortalized HLA.A2 positive human colon cancer cells (HCT116), human ovarian cancer cells (OVCAR3), and human breast cancer cells (MCF7). The control samples (“No Ag” or “VERI-000” in FIGS. 25A, 25B, and 25C) showed no background tumor killing. Together, these data demonstrate that MPV.10.34.d IRC redirects mouse and human immune responses against tumor cells in vitro.

US11858964B2. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer (2024-01-02). VerImmune Inc. [US]. Inventors: Joshua Weiyuan Wang [US], Ken Matsui [US], Philip Alan Storm [US], Kristin Marie Peters [US].
Patent 2024
Acclimatization Antigens Antiviral Agents Biological Assay Biological Factors Cancer of Colon CD8-Positive T-Lymphocytes Cell Death Cell Line, Tumor Cell Lines Cells Cell Survival Cellular Immune Response Cellular Immunity Cytotoxin Figs HLA-A2 Antigen Homo sapiens Human papillomavirus 16 In Vitro Testing Luciferases Malignant Neoplasms Mammary Carcinoma, Human MCF-7 Cells Mus Neoplasms Ovarian Cancer Patients Peptides Persistent Infection Promega Response, Immune Response Elements System, Immune T-Lymphocyte Tissue Donors Tissues UL83 protein, Human herpesvirus 5 Virus Virus Diseases
2
Optimizing hPIs Culture Conditions
Results are reported as means ± SD in all graphs. Data were processed using GraphPad Prism seven software for in vitro and in vivo experiments. In vitro tests were performed in triplicate: three different islets preparations, derived from three different donors, are used for each condition (time-points, type of medium and scaffold) for each marker. Statistical analyses were evaluated by Two-way ANOVA followed by Tukey’s multiple comparison. Comparison between low density and high density of hPIs were performed by two-way ANOVA followed by Bonferroni’s multiple comparison test. Statistical significance was set at p-value < 0.05.
Marchini A., Ciulla M.G., Antonioli B., Agnoli A., Bovio U., Visnoviz V., Bertuzzi F, & Gelain F. (2023). Long-term cultures of human pancreatic islets in self-assembling peptides hydrogels. Frontiers in Bioengineering and Biotechnology, 11, 1105157.
Publication 2023
Donors In Vitro Testing neuro-oncological ventral antigen 2, human prisma
3
Rapid Colistin Susceptibility Testing
For the qualitative assay, only the spectra acquired by the plate well without the colistin agent and those acquired by the 2 mg/L plate well (ComASP® Colistin, Liofilchem, Te, Italy) were used as growth control and test breakpoint concentration (BP) respectively. An algorithm was developed to provide a rapid and accurate detection as colistin susceptible (colS) or resistant (colR) for the 50 K. pneumoniae strains. In particular, a test sample was classified as colR or colS on the following parameters: growth control spectra score ≥ 6 and 2 mg/L spectra score > 6 or 2 mg/L spectra score < 6, respectively.
On the contrary, for the quantitative assay all the spectra acquired in the range 0.25–16 mg/L were included in the analysis along with the growth control spectra. The MIC value was determined as the lowest drug dilution at which the spectra score was <6. The geometric mean (G MEAN) and the modal MIC calculated from the replicates was reported for all the samples (Table 2). In the case the 16 mg/L spectra score was >6, a MIC value >16 mg/L was reported and the test sample classified as colR. On the contrary, in the case the 0.25 mg/L spectra score was <6, a MIC value <0.25 mg/L was reported and the sample categorized as colS.
Thus, each strain was classified according to the above mentioned algorithms for the qualitative or quantitative CORE assay.
The results were compared with those obtained by the conventional BMD test, following interpretation with the EUCAST Clinical Breakpoints (v12.0, 2022) for colistin.
According to the modal MIC value, a MIC value agreement within ±1 dilution against BMD (essential agreement, EA) was considered acceptable (Clinical laboratory testing and in vitro diagnostic test systems ISO 20776-2:2021) for the new assay evaluation.
Divergence degree in distribution between BMD and CORE assay MIC values, potentially leading to resistance state misclassification, has been statistically evaluated with a non parametric Wilcoxon Test (R statistics stats library) performed in a paired manner and with a value of p continuity correction.
Foglietta G., De Carolis E., Mattana G., Onori M., Agosta M., Niccolai C., Di Pilato V., Rossolini G.M., Sanguinetti M., Perno C.F, & Bernaschi P. (2023). “CORE” a new assay for rapid identification of Klebsiella pneumoniae COlistin REsistant strains by MALDI-TOF MS in positive-ion mode. Frontiers in Microbiology, 14, 1045289.
Publication 2023
Biological Assay cDNA Library Colistin Diagnosis In Vitro Testing Klebsiella pneumoniae MICA protein, human Pharmaceutical Preparations Strains Technique, Dilution
4
Cytotoxicity Evaluation of AMP-NPs and BLF-NPs on HCE-2 Cells

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Atmosphere Biological Assay Bos taurus Bromides Cells Cell Survival CES2 protein, human Cornea Cytotoxin Epidermal growth factor Epithelial Cells Eye Homo sapiens Hydrocortisone Insulin In Vitro Testing Keratinocyte Obstetric Delivery Penicillins Pharmaceutical Solutions Rehabilitation Serum Streptomycin Sulfoxide, Dimethyl
5
Development and Validation of Neuro-stack
The Neuro-stack is a neural interface that was designed, validated and tested in human participants all at an academic center, unlike other existing devices discussed (for example, NeuroPace, Medtronic and Blackrock Microsystems), which were developed in commercial environments. The Neuro-stack development was informed by in vivo human testing (for example, wearability, pre-existing stimulation protocols and available online electrophysiological data processing), all of which were made possible by research and close collaboration among academic researchers across the Departments of Electrical and Computer Engineering, Neurosurgery and Neurology and the Neuroscience Interdepartmental Program at UCLA.
As mentioned previously, much of the hardware (Sense, Spike and Stim ICs) integrated in the Neuro-stack was developed for the implantable SUBNETS system through a multi-institutional effort that was initiated, supported and funded by DARPA. The SUBNETS system and its components were developed following standard operating procedures and FDA guidance for active implantable medical devices incorporating requisite International Organization for Standardization (ISO) standards. In addition to the Sense IC for LFPs and Stim IC for the SUBNETS program, an additional Sense IC for spikes and a PLS IC were developed, conforming to the same guidelines. The technology incorporated in the Neuro-stack was developed in two fabrication cycles (1st iteration40 and 2nd iteration39 (link)), with a series of tests involving benchtop verification with in vitro validation. In the final version of the system, Sense, Spike and PLS ICs were designed and fabricated at Taiwan Semiconductor Manufacturing Company using a 40-nm complementary metal-oxide semiconductor (CMOS), whereas the Stim IC was fabricated at X-FAB using a high-voltage 180-nm CMOS. Neuro-stack assembly and software development were internally verified and validated at UCLA to meet safety requirements set by the FDA and the UCLA IRB. The functionality of each hardware and software component was, thus, thoroughly tested and documented before obtaining IRB approval. This included testing of recording functionalities at specified parameters for a given channel, at a defined sampling frequency and under a specific amplifier configuration and not others. Likewise, validation of stimulation capability was done to ensure that software control and triggering of stimulation delivered current with the exact programmed parameters, as per ISO 14708-1 and ISO 14708-3. Given that stimulation requires additional safety checks, a separate condition, which enables stimulation, needed to be checked at the firmware level to ensure that delivery could happen only during triggered stimulation trials and not others. This ensured a redundant check in cases where an altered command would be read by the firmware as a stimulation command. Furthermore, all commands sent to the firmware contained an 8-bit cyclic redundancy check (CRC) code to reduce the probability of an incorrect command delivery. During validation and human in vivo testing, only one password-protected and encrypted experimental computer containing a signed certificate was used to control the Neuro-stack, thus simplifying the necessary security infrastructure required for a commercial medical device.
Leakage currents of all channels were verified independently of software and hardware designers by a clinical engineer in an idle, active recording and stimulation mode of operation. Furthermore, all hardware and software documentation, including but not limited to design history, schematics, code and in vitro validation tests, were reviewed and approved by an independent clinical engineer at the UCLA Ronald Reagan Medical Center as precursor to the IRB review process.
Topalovic U., Barclay S., Ling C., Alzuhair A., Yu W., Hokhikyan V., Chandrakumar H., Rozgic D., Jiang W., Basir-Kazeruni S., Maoz S.L., Inman C.S., Stangl M., Gill J., Bari A., Fallah A., Eliashiv D., Pouratian N., Fried I., Suthana N, & Markovic D. (2023). A wearable platform for closed-loop stimulation and recording of single-neuron and local field potential activity in freely moving humans. Nature Neuroscience, 26(3), 517-527.
Publication 2023
Electricity Homo sapiens In Vitro Testing Medical Devices Metals Nervousness Neurosurgical Procedures Obstetric Delivery Oxides Safety Secure resin cement

Top products related to «In Vitro Testing»

1
Prism 7 by GraphPad
Sourced in United States, Japan, United Kingdom, Austria, Canada, Germany, Poland, Belgium, Lao People's Democratic Republic, China, Switzerland, Sweden, Finland, Spain, France
GraphPad Prism 7 is a data analysis and graphing software. It provides tools for data organization, curve fitting, statistical analysis, and visualization. Prism 7 supports a variety of data types and file formats, enabling users to create high-quality scientific graphs and publications.
2
Prism 6 by GraphPad
Sourced in United States, United Kingdom, Canada, China, Germany, Japan, Belgium, Israel, Lao People's Democratic Republic, Italy, France, Austria, Sweden, Switzerland, Ireland, Finland
Prism 6 is a data analysis and graphing software developed by GraphPad. It provides tools for curve fitting, statistical analysis, and data visualization.
3
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
4
Prism 5 by GraphPad
Sourced in United States, Germany, United Kingdom, Israel, Canada, Austria, Belgium, Poland, Lao People's Democratic Republic, Japan, China, France, Brazil, New Zealand, Switzerland, Sweden, Australia
GraphPad Prism 5 is a data analysis and graphing software. It provides tools for data organization, statistical analysis, and visual representation of results.
5
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
6
Prism 8 by GraphPad
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.
7
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
8
Excella e24 by Eppendorf
Sourced in Germany, United States, Italy
The Excella E24 is a centrifuge designed for general laboratory use. It is capable of holding 24 microtubes or 4 microplates. The Excella E24 features a brushless motor and digital speed control for precise operation.
9
Penicillin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, Switzerland, Brazil, China, Poland, Macao, Spain, Canada, Japan, Australia, Austria, Belgium, Israel, Sao Tome and Principe, Netherlands, India, Sweden, Ireland, Argentina, Czechia, Denmark, New Zealand, Hungary, Mexico, Holy See (Vatican City State), Ukraine
Penicillin is a type of antibacterial drug that is widely used in medical and laboratory settings. It is a naturally occurring substance produced by certain fungi, and it is effective against a variety of bacterial infections. Penicillin works by inhibiting the growth and reproduction of bacteria, making it a valuable tool for researchers and medical professionals.
10
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.

More about "In Vitro Testing"

In Vitro Testing, also known as in vitro evaluation or in vitro experimentation, is a crucial scientific technique used to assess the properties and characteristics of various substances, products, or processes outside of a living organism.
This approach is widely employed in fields like scientific research, pharmaceutical development, and toxicology studies to evaluate the safety, efficacy, and underlying mechanisms of different compounds or procedures before moving to in vivo (animal or human) testing.
The key advantage of In Vitro Testing is its ability to provide controlled, reproducible experiments that offer valuable insights into cellular, molecular, and biochemical processes without the complexities of a living system.
This streamlined approach enables researchers to optimize protocols, identify lead candidates, and accelerate the development of new therapies or products in a more cost-effective and efficient manner.
In the context of scientific research, In Vitro Testing is often conducted using cell cultures, tissue samples, or biochemical assays.
This technique allows for the evaluation of various parameters, such as cell viability, proliferation, gene expression, enzyme activity, and drug-target interactions.
By leveraging the insights gained from In Vitro Testing, scientists can refine their research strategies, making more informed decisions about which compounds or procedures to advance to the next stage of development.
In the pharmaceutical industry, In Vitro Testing plays a crucial role in the drug discovery and development process.
It is used to assess the safety, pharmacokinetics, and pharmacodynamics of potential drug candidates, helping to identify the most promising compounds for further investigation.
This approach also enables researchers to understand the mechanisms of action, target engagement, and potential adverse effects of drug molecules, ultimately streamlining the development of new therapies.
In the field of toxicology, In Vitro Testing is employed to evaluate the potential toxicity of chemicals, cosmetics, or other substances.
By conducting experiments on cell cultures or tissue samples, researchers can assess the cytotoxicity, genotoxicity, and other toxicological endpoints, providing valuable information to regulatory agencies and product developers.
The versatility of In Vitro Testing is further enhanced by the integration of advanced technologies, such as GraphPad Prism, a powerful data analysis and visualization software.
Tools like Prism 6, Prism 7, and Prism 8 enable researchers to analyze their experimental data, generate high-quality graphs, and perform statistical analyses, ultimately enhancing the quality and reliability of their In Vitro Testing results.
Moreover, the availability of key culture media components, such as Fetal Bovine Serum (FBS), Penicillin, Streptomycin, and Dulbecco's Modified Eagle Medium (DMEM), play a crucial role in supporting cell growth and maintaining the integrity of In Vitro Testing systems.
These essential reagents and culture conditions ensure the optimal performance and reproducibility of in vitro experiments.
In conclusion, In Vitro Testing is a versatile and indispensable tool in the world of scientific research, pharmaceutical development, and toxicology.
By leveraging the insights gained from this technique, researchers can make more informed decisions, optimize their protocols, and accelerate the development of new products and therapies, ultimately contributing to advancements in various fields of study.